Estrogen receptor gene amplification occurs rarely in ovarian cancer (Q44039602)

2

1 reference

29 November 2017

Tobias Grob

3

1 reference

29 November 2017

Luigi Terracciano

6

1 reference

29 November 2017

Matthias Choschzick

7

1 reference

29 November 2017

Guido Sauter

https://scigraph.springernature.com/pub.10.1038/modpathol.2008.130

8

1 reference

29 November 2017

8 August 2008

1 reference

29 November 2017

1 reference

29 November 2017

22

1 reference

29 November 2017

191-196

1 reference

29 November 2017

2

1 reference

29 November 2017

0 references

cites work

Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Validation of tissue microarray technology in ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Estrogen and progesterone receptors in ovarian epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Estrogen, progesterone and epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Hormone therapy in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Estrogen action in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Estrogens and epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Amplification and Overexpression of the L-MYC Proto-Oncogene in Ovarian Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Second-line therapy of advanced ovarian cancer with GnRH analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Tamoxifen in the treatment of recurrent ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Correlations between c-myc gene copy-number and clinicopathological parameters of ovarian tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

[Estrogen and progesterone receptors in malignant ovarian neoplasms]

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

Amplification of HER-2/neu oncogene in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection ofcyclin D1 in breast andcyclin E in ovarian tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

Aromatase inhibitors in ovarian cancer: is there a role?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021

The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.130

7 January 2021